Profile data is unavailable for this security.
About the company
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-47.58m
- Incorporated2021
- Employees34.00
- LocationSenti Biosciences Inc2 Corporate Drive, First FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 239-2030
- Fax+1 (302) 655-5049
- Websitehttps://www.sentibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 19.89m | 4.00 | -- | 345.16 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 19.92m | 6.00 | -- | -- | -- | 56.85 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 20.03m | 59.00 | -- | 0.2964 | -- | 27.22 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.52m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 20.75m | 26.00 | -- | 2.28 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.36m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 21.57m | 7.00 | -- | 2.45 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.78m | 7.00 | -- | 0.7632 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.84m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 21.87m | 34.00 | -- | 2.69 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 22.08m | 1.00 | -- | 0.7388 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 22.67m | 66.00 | -- | -- | -- | 2.43 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 22.73m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
| LAMY | 0.00 | 106.70k | 23.10m | -- | 24.05 | -- | 190.26 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.20m | -- | -- | 0.6831 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 23.84m | 5.00 | -- | 1.30 | -- | 5.08 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Senti Biosciences Inc's reporting currency: US Dollar USD
7.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 888.00k | 3.38% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 537.50k | 2.04% |
| Geode Capital Management LLCas of 31 Dec 2025 | 144.80k | 0.55% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 132.37k | 0.50% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 91.19k | 0.35% |
| Citadel Securities LLCas of 30 Sep 2025 | 82.75k | 0.32% |
| Jane Street Capital LLCas of 31 Dec 2025 | 38.43k | 0.15% |
| XTX Markets LLCas of 30 Sep 2025 | 26.57k | 0.10% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 21.93k | 0.08% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 16.31k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
